Fetal sheep cells

animal tissue

provenance:animal tissue

first introduced:1931

regulatory status:banned

context:Paul Niehans first used animal-tissue injection in 1931 with calf parathyroid material during an emergency case at his Bern surgical practice. He subsequently standardized on fetal lamb tissue as the donor source for his cellular-therapy protocol at Clinique La Prairie at Clarens. Fetal tissue was selected on the premise of higher 'cellular vitality' and the assumed absence of immune-reactive markers in fetal cells. The immunological premise was not borne out by subsequent research, but it set the template for the protocol that the clinic used for the remainder of Niehans's career.

MECHANISM CLAIMED

Cells from a specific organ of a freshly killed lamb fetus, when injected into a human recipient, will migrate selectively to the corresponding organ in the recipient and restore its function through cellular replacement and rejuvenation.

MECHANISM ACTUAL

Xenogeneic cells injected subcutaneously or intramuscularly into a human recipient are recognized as foreign by the recipient's immune system and destroyed. Organ-specific migration and integration of xenogeneic cells across the species barrier is not biologically supported. Reported clinical effects in case literature are consistent with placebo response, concurrent care, and selection bias in the patient population.

INTERVENTIONS USING IT

Cellular therapy (Frischzellentherapie)

NOTES

Fetal sheep cells, in the Niehans protocol, are macerated tissue preparations from a freshly killed lamb fetus, selected for organ correspondence with the recipient organ targeted for treatment. The preparation is administered subcutaneously or intramuscularly within hours of harvest. The selection of fetal tissue rests on the premise that fetal cells are biologically more potent and less immunogenic than adult cells; the premise is broadly correct in narrow contexts (early-gestation cells do express fewer mature MHC molecules) but does not translate into the cross-species, organ-specific cellular replacement that the Niehans protocol claims. The ingredient is now banned within recognized medicine in Switzerland and Germany.